CNS pipeline · person
Glenn Short, Ph.D.
Drug-development scientist who served as Chief Executive Officer of EmpathBio, atai Life Sciences' wholly owned subsidiary developing the MDMA derivative EMP-01 for PTSD. He holds a Ph.D. and has held roles across atai's platform, later serving as a senior research/development leader at the company.
- 2 companies
Courtesy AtaiBeckley
Current roles
- Atai Beckley N.V. (AtaiBeckley)Chief Scientific Officer · Executive
- EmpathBio, Inc.Chief Executive Officer · Executive
Appears with
People sharing a company with Glenn.
- Amir Kalali · Atai Beckley N.V. (AtaiBeckley)
- Andrea Heslin Smiley · Atai Beckley N.V. (AtaiBeckley)
- Anne Johnson · Atai Beckley N.V. (AtaiBeckley)
- Christian Angermayer · Atai Beckley N.V. (AtaiBeckley)
- Cosmo Feilding Mellen · Atai Beckley N.V. (AtaiBeckley)
- Florian Brand · Atai Beckley N.V. (AtaiBeckley)
- Gerd Kochendoerfer · Atai Beckley N.V. (AtaiBeckley)
- John Hoffman · Atai Beckley N.V. (AtaiBeckley)
- Kevin Craig · Atai Beckley N.V. (AtaiBeckley)
- Laurent Fischer · Atai Beckley N.V. (AtaiBeckley)
- Michael Faerm · Atai Beckley N.V. (AtaiBeckley)
- Robert Conley · Atai Beckley N.V. (AtaiBeckley)
- Robert Hershberg · Atai Beckley N.V. (AtaiBeckley)
- Ryan Barrett · Atai Beckley N.V. (AtaiBeckley)
- Sabrina Martucci Johnson · Atai Beckley N.V. (AtaiBeckley)
- Scott Braunstein · Atai Beckley N.V. (AtaiBeckley)
- Srinivas Rao · Atai Beckley N.V. (AtaiBeckley)
People and affiliation data assembled from public company disclosures, SEC filings, and conference materials — every record source-cited under psychiatrist-authored guardrails.